The prediction of individual differences in response to D-amphetamine in healthy adults

Behavioural Pharmacology

Volumn 14, Issue 1, 2003, Pages 19-32

  Alessi, Sheila M ^a   Greenwald, M ^b   Johanson, C E ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Amphetamine; Cortisol; Drug reinforcement; Human; Individual differences; Motor activity; Prepulse inhibition; Startle reflex

Indexed keywords

DEXAMPHETAMINE; HYDROCORTISONE; PLACEBO;

ACOUSTIC REFLEX; ADULT; ARTICLE; BEHAVIOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HEALTH STATUS; HORMONE DETERMINATION; HUMAN; MOTOR ACTIVITY; NORMAL HUMAN; PERSONALITY; PREDICTION; PREPULSE INHIBITION; REINFORCEMENT; SALIVA LEVEL; SENSATION; STARTLE REFLEX;

EID: 0037325908     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200302000-00002     Document Type: Article

References (74)

1. Abduljawad KA, Langley RW, Bradshaw CM, Szabadi E (1998). Effects of bromocriptine and haloperidol on prepulse inhibition of the acoustic startle response in man. J Psychopharmacol 12:239-245.
2. Abduljawad KA, Langley RW, Bradshaw CM, Szabadi E (1999). Effects of bromocriptine and haloperidol on prepulse inhibition: comparison of the acoustic startle eyeblink response and the N1/P2 auditory-evoked response in man. J Psychopharmacol 13:3-9.
3. al'Absi M, Bongard S, Buchanan TW, Pincomb GA, Licinio J, Lovallo WR (1997). Cardiovascular and neuroendocrine adjustment to public speaking and mental arithmetic stressors. Psychophysiology 34:266-275.
4. Angrist B, Corwin J, Bartlik B, Cooper T (1987). Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biol Psychiatry 22:1357-1368.
5. Anthony B (1992). Blink modulation in attention-deficit disorder. Psychophysiology 27:6.
6. Bakshi VP, Geyer MA, Taaied N, Swerdlow NR (1995). A comparison of the effects of amphetamine, strychnine and caffeine on prepulse inhibition and latent inhibition. Behav Pharmacol 6:801-809.
7. Braff DL, Grillon C, Geyer MA (1992). Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49:206-215.
8. Broadbear JH, Winger G, Cicero TJ, Woods JH (1999a). Effects of self-administered cocaine on plasma adrenocorticotropic hormone and cortisol in male rhesus monkeys. J Pharmacol Exp Ther 289:1641-1647.
9. Broadbear JH, Winger G, Cicero TJ, Woods JH (1999b). Effects of response contingent and noncontingent cocaine injection on hypothalamlc-pituitary-adrenal activity in rhesus monkeys. J Pharmacol Exp Ther 290:393-402.
10. Broadbear JH, Winger G, Woods JH (1999c). Cocaine-reinforced responding in rhesus monkeys: Pharmacological attenuation of the hypothalamic-pituitary-adrenal axis response. J Pharmacol Exp Ther 290:1347-1355.
11. Buchanan TW, al'Absi M, Lovallo WR (1999). Cortisol fluctuates with increases and decreases in negative affect. Psychoneuroendocrinology 24:227-241.
12. Cadenhead KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL (2000). Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry 157:1660-1668.
13. Chait LD (1993). Factors influencing the reinforcing and subjective effects of D-amphetamine in humans. Behav Pharmacol 4:191-199.
14. Cloninger CR (1987). A systematic method for clinical description and classification of personality variants. Arch Gen Psychiatry 44:573-588.
15. Cook EW III, Atkinson L, Lang PJ (1987). Stimulus control and data acquisition for IBM PCs and compatibles. Psychophysiology 24:726-727.
16. Davidson RA, Smith B D (1991). Caffeine and novelty: effects on electrodermal activity and performance. Physiol Behav 49:1169-1175.
17. Davis M, Falls WA, Campeau S, Munsoo K (1993). Fear-potentiated startle: a neural and pharmacological analysis. Behav Brain Res 58:175-198.
18. Dawson ME, Schell AM, Hazlett EA, Nuechterlein KH, Filion DL (2000). On the clinical and cognitive meaning of impaired sensorimotor gating in schizophrenia. Psychiatry Res 96:187-197.
19. de Wit H, Bodker B (1994). Personality and drug preference in normal volunteers. Int J Addict 29:1617-1630.
20. de Wit H, Uhlenhuth EH, Johanson CE (1987). Individual differences in behavioral and subjective responses to alcohol. Alcohol Clin Exp Res 11:52-59.
21. Dews PB (1958). Studies of behavior. IV. Stimulant actions of methamphetamine. J Pharmacol Exp Ther 122:137-147.
22. Dews PB, Wenger GR (1977). Rate-dependency of the behavioral effects of amphetamine. Adv Behav Pharmacol 1:167-227.
23. Fagan JF (1970). Memory in the infant. J Exp Child Psychol 9:217-226.
24. First MB, Spitzer RL, Gibbon M, Williams JBW (1995). Structured Clinical Interview of DSM-IV Axis I Disorders - patient edition (SCID J/P, Version 2). Washington, DC: American Psychiatric Press.
25. Foltin RW, Fischman MW (1991). Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 28:3-48.
26. Greenwald MK, Bradley MM, Cuthbert BN, Lang P J (1998a). Startle potentiation: Shock sensitization, aversive learning, and affective picture modulation. Behav Neurosci 112:1069-1079.
27. Greenwald MK, Schuster C R, Johanson CE, Jewell J (1998b). Automated measurement of motor activity in human subjects: Effects of repeated testing and D-amphetamine. Pharmacol Biochem Behav 59:1-7.
28. Griffiths RR, Troisi JR, Silverman K, Mumford GK (1993). Validation of the multiple-choice procedure for investigating drug reinforcement in humans. Behav Pharmacol 4:3-13.
29. Griffiths RR, Rush CR, Puhala KA (1996). Validation of the multiple-choice procedure for investigating drug reinforcement in humans. Exp Clin Psychopharmacol 4:97-106.
30. Grillon C, Davis M (1997). Effects of stress and shock anticipation on prepulse inhibition of the startle reflex. Psychophysiology 34:511-517.
31. Grillon C, Ameli R, Charney DS, Krystal J, Braff DL (1992). Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol Psychiatry 32:939-943.
32. Grillon C, Merikangas KR, Dierker L, Snidman N, Arriaga RI, Kagan J, et al. (1999). Startle potentiation by threat of aversive stimuli and darkness in adolescents: a multi-site study. Int J Psychophysiol 32:63-73.
33. Haertzen CA (1966). Development of scales based on patterns of drug effects using the Addiction Research Center Inventory (ARCI). Psychol Rep 18:163-194.
34. Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW (2001). Methamphetamine self-administration by humans. Psychopharmacology 157:75-81.
35. Harwood HJ, Napolitano DM, Kristiansen PL, Collins JJ (1984). Economic Costs to Society of Alcohol and Drug Abuse and Mental Illness: 1980. Research Triangle Institute, Research Triangle, NC, report 2734/00-01FR to Alcohol, Drug Abuse and Mental Health Administration. Rockville, MD: Office of Program Planning and Coordination.
36. Hazlett EA, Buchsbaum MS, Haznedar MM, Singer MB, Germans MK, Schnur DB, et al. (1998). Prefrontal codex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology 35:186-198.
37. Hazlett EA, Buchsbaum MS, Tang CY, Fleischman MB, Wei TC, Byne W, et al. (2001). Thalamic activation during an attention-to-prepulse startle modification paradigm: a functional MRI study. Biol Psychiatry 15:281-291.
38. Hutchison KE, Swift R (1999). Effects of D-amphetamine on prepulse inhibition of the startle reflex in humans. Psychopharmacology 143:394-400.
39. Hutchinson KE, Wood MD, Swift R (1999). Personality factors moderate subjective and psychophysiological responses to D-amphetamine in humans. Exp Clin Psychopharmacol 7:493-501.
40. Johanson CE, de Wit H (1989). The use of choice procedures for assessing the reinforcing properties of drugs in humans. NIDA Research Monograph 92:171-210.
41. Johanson CE, Schuster CR (1975). A choice procedure for drug reinforces: cocaine and methylphenidate in the rhesus monkey. J Pharmacol Exp Ther 193:676-688.
42. Johanson CE, Uhlenhuth EH (1980a). Drug preference and mood in humans: D-amphetamine. Psychopharmacology 71:275-279.
43. Johanson CE, Uhlenhuth EH (1980b). Drug preference and mood in humans: Diazepam. Psychopharmacology 71:269-273.
44. Kaviani H, Gray JA, Checkley SA, Kumari V, Wilson GD (1999). Modulation of the acoustic startle reflex by emotionally-toned film-clips. Int J Psychophysiol, 32:47-54.
45. Kodsi MH, Swerdlow NR (1997). Regulation of prepulse inhibition by ventral pallidal projections. Brain Res Bull 43:219-228.
46. Leander JD, McMillan DE (1974). Rate-dependent effects of drugs. 1. Comparisons of D-amphetamine, pentobarbital and chlorpromazine on multiple and mixed schedules. J Pharmacol Exp Ther 188:726-739.
47. Lovallo WR, Pincomb GA, Bracket DJ, Wilson MF (1990). Heart rate reactivity as a predictor of neuroendocrine responses to aversive and appetitive challenges. Psychosom Med 52:17-26.
48. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971). Physiologic, subjective and behavioral effects of amphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245-258.
49. McNair DM, Lorr M, Droppleman LF (1971). Manual for the Profile of Mood States. San Diego: Educational and Industrial Testing Service.
50. Ott DA, Mandel RJ (1995). Amphetamine sensitivity in open-field activity vs. the prepulse inhibition paradigm. Brain Res Bull 37:219-222.
51. Piazza PV, Deminière JM, Le Moal M, Simon H (1989). Factors that predict individual vulnerability to amphetamine self-administration. Science 245:1511-1513.
52. Piazza PV, Deminière JM, Maccari S, Mormède P, Le Moal M, Simon H (1990). Individual reactivity to novelty predicts probability of amphetamine self-administration. Behav Pharmacol 1:339-345.
53. Piazza PV, Maccari S, Deminière JM, Le Moal M, Mormède P, Simon H (1991). Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc Natl Acad Sci USA 88:2088-2092.
54. Rapoport JL, Buchsbaum MS, Zahn TP, Wiengartner H, Ludlow C, Mikkelsen EJ (1978). Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science 199:560-563.
55. Rapoport JL, Buchsbaum MS, Weingartner H, Zahn TP, Ludlow C, Mikkelsen EJ (1980). Dextroamphetamine: Its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 37:933-943.
56. Rose RM, Kreuz LE, Holaday JW, Sulak KJ, Johnson CE (1972). Diurnal variation of plasma testosterone and cortisol. J Endocrinol 54:177-178.
57. Rush CR, Essman WD, Simpson CA, Baker RW (2001). Reinforcing and subject-rated effects of methylphenidate and D-amphetamine in non-drug-abusing humans. J Clin Psychopharmacol 21:273-286.
58. Schell AM, Dawson ME, Hazlett EA, Filion DL (1995). Attentional modulation of startle in psychosis-prone college students. Psychophysiology 32:266-273.
59. Schell AM, Wynn JK, Dawson ME, Sinaii N, Niebala CB (2000). Automatic and controlled attentional processes in startle eyeblink modification: effects of habituation of the prepulse. Psychophysiology 37:409-417.
60. Substance Abuse and Mental Health Services Administration (2002). Results from the 2001 National Household Survey on Drug Abuse: Volume I. Summary of National Findings. NHSDA Series H-17, DHHS Publication No. SMA 023758. Rockville, MD: Office of Applied Studies.
61. Schwarzkopf SB, McCoy L, Smith DA, Boutros NN (1993). Test-retest reliability of prepulse inhibition of the acoustic startle response. Biol Psychiatry 34:896-900.
62. Simons RF, Giardina BD (1992). Reflex modification in psychosis-prone young adults. Psychophysiology 29:8-16.
63. Swerdlow NR, Mansbach RS, Geyer MA, Pulvirenti L, Koob GF, Braff DL (1990). Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharmacology (Berl) 100:413-416.
64. Swerdlow NR, Auerbach P, Monroe SM, Hartston H, Geyer MA, Braff DL (1993). Men are more inhibited than women by weak prepulses. Biol Psychiatry 34:253-260.
65. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994). Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139-154.
66. Swerdlow NR, Filion D, Geyer MA, Braff DL (1995). 'Normal' personality correlates of sensorimotor, cognitive, and visuospatial gating. Biol Psychiatry 37:286-299.
67. Tiitinen H, May P, Reinikainen K, Naatanen R (1994). Attentive novelty detection in humans is governed by pre-attentive sensory memory. Nature 372:90-92.
68. Ward AS, Collins ED, Haney M, Foltin RW, Fischman MW (1998). Ketoconazole attenuates the cortisol response but not the subjective effects of smoked cocaine in humans. Behav Pharmacol 9:577-586.
69. Ward AS, Collins ED, Haney M, Foltin RW, Fischman MW (1999). Blockade of cocaine-induced increases in adrenocorticotrophic hormone and cortisol does not attenuate the subjective effects of smoked cocaine in humans. Behav Pharmacol 10:523-529.
70. Warner LA, Kessler RC, Hughes M, Anthony JC, Nelson CB (1995). Prevalence and correlates of drug use and dependence in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 52:219-229.
71. Wilder J (1931). The 'law of initial values', a neglected biological law and its significance for research and practice. In: Porges SW, Coles MGH (editors): Psychophysiology. Streudsberg: Dewden, Hutchinson and Row; pp. 38-46.
72. Zacny JP, Bodker BK, de Wit H (1992). Effects of setting on the subjective and behavioral effects of D-amphetamine in humans. Addict Behav 17:27-33.
73. Zuckerman M (1984). Sensation seeking: A comparative approach to a human trait. Brain Behav Sci 7:413-471.
74. Zuckerman M, Eysenck S, Eysenck HJ (1978). Sensation seeking in England and America: Cross-cultural, age, and sex comparisons. J Consult Clin Psychol 46:139-149.